South Korea has developed the world's first recombinant protein-based anthrax vaccine, a major step toward self-sufficiency ...

The anthrax vaccine is deemed safe and effective in protecting people from anthrax infection. However, there have been some concerns about its safety in the past, and its use remains controversial.

The company’s only product was the anthrax vaccine, called BioThrax, which it sold chiefly to the U.S. military. In mid-2004, the company reorganized as Emergent BioSolutions.

Phatisa sells Deltamune to Vaxxinova, expanding animal health capabilities across Africa and strengthening regional vaccine production and innovation.

The anthrax vaccine isn’t approved for use after exposure, but that might change in an emergency situation, such as if anthrax were used in terrorism. In that case, ...

The committee is meeting for the first since Robert F. Kennedy Jr. abruptly dismissed all 17 members and replaced them with a ...

A key vaccine-focused committee of the Centers for Disease Control and Prevention met Wednesday despite bipartisan ...

A federal vaccine advisory committee plans to review the childhood vaccination schedule and scrutinize vaccines that have ...

A little less than a year after topping up its medical countermeasure contracts with Emergent BioSolutions, the federal ...

Kim Gab-jung, right, director general of the Korea Disease Control and Prevention Agency's department of disease diagnosis and analysis, answers questions during a press briefing on the development of ...